This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción AKUS
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Akouos, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.29 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$2.32 |
| Beta | -0.56 |
| 1 Month Change | 1.22% |
| 3 Month Change | 270.20% |
| 1 Year Change | 50.34% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.59% |
Noticias y actualizaciones recientes
Recent updates
Is Akouos (NASDAQ:AKUS) In A Good Position To Deliver On Growth Plans?
Sep 19
Akouos stock rises 11% on FDA nod to start gene therapy trial for hearing loss
Sep 13We Think Akouos (NASDAQ:AKUS) Needs To Drive Business Growth Carefully
Jun 04We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Feb 19Companies Like Akouos (NASDAQ:AKUS) Are In A Position To Invest In Growth
Oct 28Here's Why We're Not Too Worried About Akouos' (NASDAQ:AKUS) Cash Burn Situation
Jun 26Akouos names Kathy Reape as chief development officer
May 07We Think Akouos (NASDAQ:AKUS) Can Afford To Drive Business Growth
Mar 04Did Akouos, Inc. (NASDAQ:AKUS) Insiders Buy Up More Shares?
Jan 10Akouos (NASDAQ:AKUS) Is In A Good Position To Deliver On Growth Plans
Nov 18Rentabilidad de los accionistas
| AKUS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.9% | -1.5% | -0.7% |
| 1Y | 50.3% | 0.1% | 22.3% |
Rentabilidad vs. Industria: AKUS exceeded the US Biotechs industry which returned -10.3% over the past year.
Rentabilidad vs. Mercado: AKUS exceeded the US Market which returned -16.1% over the past year.
Volatilidad de los precios
| AKUS volatility | |
|---|---|
| AKUS Average Weekly Movement | 27.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: AKUS's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: AKUS's weekly volatility has increased from 20% to 28% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2016 | 103 | Manny Simons | www.akouos.com |
Resumen de fundamentos de Akouos, Inc.
| Estadísticas fundamentales de AKUS | |
|---|---|
| Capitalización bursátil | US$491.02m |
| Beneficios(TTM) | -US$92.59m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-5.3x
Ratio precio-beneficio (PE)¿Está AKUS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AKUS | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$92.59m |
| Beneficios | -US$92.59m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.51 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado AKUS a largo plazo?
Ver rendimiento histórico y comparativa